MedTrace Logo

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

NCT05900882 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-08-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of SVRd in NDMM patients presenting with extramedullary disease.

Conditions

Interventions

DRUG

Selinexor

Selinexor 60 mg/day, orally on d1,8,15,22

DRUG

Bortezomib

Bortezomib 1.3mg/m2 intravenously on d1,8,15,22

DRUG

Lenalidomide

Lenalidomide 25 mg/d (the dose will be adjusted according to creatinine clearance)

DRUG

Dexamethasone

Dexamethasone 20 mg/day orally on d1-2, d8-9,d15-16,d22-23

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Lijuan Chen · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-15
Primary Completion
2025-08-30
Completion
2025-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05900882 on ClinicalTrials.gov